Rokit Healthcare, a leading company in long-term regeneration platforms, announced on March 30 that it has secured a patent in the U.S. for its kidney regeneration technology, following similar registrations in Korea and Japan.
This groundbreaking U.S. patent utilizes the patient’s own omentum-derived tissue to structurally regenerate damaged kidney tissue. With this achievement, Rokit Healthcare has now secured intellectual property rights in the world’s three major medical markets: Korea, Japan, and the U.S., solidifying its position in the organ regeneration field.
Following this U.S. patent acquisition, Rokit Healthcare plans to intensify its collaboration with Harvard Medical School (Mass General Brigham). A key driver of this partnership is the joint research agreement signed in February with Professor Joseph Bonventre, a world-renowned authority and former president of the Global Society for Kidney Regeneration.
The collaboration with Bonventre’s team aims to advance kidney regeneration and expand access to treatment, addressing challenges that existing technologies, such as new drug development and kidney transplantation, have failed to resolve.
Rokit Healthcare intends to elevate its advanced regeneration technology, already validated through four years of research with domestic medical professionals, to a global commercialization level through its joint research with Harvard. This strategy will facilitate rapid applications for Expanded Access Programs (EAP) worldwide, offering timely treatment opportunities to kidney patients.
Industry experts view this patent registration as a crucial milestone. They note that Rokit Healthcare’s next challenge is to demonstrate whether its artificial intelligence (AI) regeneration therapy can achieve complete regeneration rather than merely extending kidney function. The company aims to shift focus from traditional management-centered treatment to addressing the root causes of diseases.
Rokit Healthcare has established itself as a platform company by completing a unique full-stack business model encompassing diagnosis, treatment, and monitoring. Its AI platform, AI Kidney, which predicts kidney function from a single drop of blood within five years, has already secured a high-revenue royalty structure of approximately 18% through global licensing.
The integration of the newly patented kidney regeneration platform will enable personalized regeneration solutions for patients with estimated glomerular filtration rate (eGFR) stages 2 to 5. This marks a shift from one-time treatments to a model generating continuous revenue through data accumulation, potentially reducing the ten-year dialysis costs in the U.S. (approximately 900,000 USD) by over half.
The global kidney dialysis market is estimated at about 140 trillion KRW (about 91 billion USD), with approximately 850 million chronic kidney disease patients worldwide. Market experts identify Rokit Healthcare’s target group – patients in the pre-dialysis stage (eGFR stages 2 to 4) – as a critical golden timing market urgently needing treatment alternatives. Capturing even 1% of this market could yield revenues in the hundreds of billions of KRW (about 650,900 USD) and substantial data royalties for Rokit Healthcare.
The company emphasized that this achievement completes the final piece in developing its AI organ prediction and regeneration platform. They stated that it is now seeing the realization of a global regenerative medicine full-stack platform that integrates AI diagnostics from Johns Hopkins, kidney regeneration research from Harvard, and surgical infrastructure from Northwell Health.